An innovative research effort has found that providing pluripotent cells to developing infants affected by spina bifida as part of a surgical repair may represent a "important advancement" in managing prenatal disorders.
Trial Details and Safety
The US-based trial involved six unborn babies with myelomeningocele. Surgeons applied placenta-derived mesenchymal stem cells directly onto the baby's spinal cord while the defect was being closed.
Significantly, the stem cell application proved to be secure. Researchers confirmed that the therapy did not induce cancerous growths, hinder surgical recovery, or impede the resolution of associated brain abnormalities.
Promising Outcomes
Imaging conducted after delivery showed a full resolution of brainstem displacement in each of the babies. This neurological improvement is a key indicator for enhanced physical outcomes.
"If it makes a greater number of infants able to walk who wouldn't have, then it would become the conventional approach," said the lead researcher. "The outcomes appear profoundly encouraging and create a pathway toward lots of potential novel therapies."
Long-Term Prospects and Optimism
Experts not involved in the trial indicated that subsequent studies of these apparent benefits could announce a "new era" in in-utero treatment. The potential to improve neurological damage occurring during fetal development is considered a transformative goal.
Notably important would be improvements in bladder and bowel function, which are typical difficulties for people affected by this defect.
The Path Forward
Although this preliminary study focused on a handful of cases, its confirmed tolerability and hopeful trends create a solid basis for broader investigative efforts. The addition of cellular treatment with current in-utero repair procedures holds considerable promise for changing life trajectories for infants diagnosed prenatally with this neural tube defect.